BridgeBio Pharma/$BBIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BridgeBio Pharma
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Ticker
$BBIO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
728
ISIN
US10806X1028
Website
BridgeBio Pharma Metrics
BasicAdvanced
$7.3B
-
-$3.54
1.08
-
Price and volume
Market cap
$7.3B
Beta
1.08
52-week high
$39.54
52-week low
$21.62
Average daily volume
3.1M
Financial strength
Current ratio
5.139
Quick ratio
4.312
Long term debt to equity
-113.4
Total debt to equity
-113.4
Interest coverage (TTM)
-5.67%
Management effectiveness
Return on assets (TTM)
-48.27%
Return on equity (TTM)
50.59%
Valuation
Price to revenue (TTM)
56.852
Price to book
-4.42
Price to tangible book (TTM)
-4.34
Price to free cash flow (TTM)
-14.219
Growth
Revenue change (TTM)
-41.71%
Earnings per share change (TTM)
11.20%
3-year revenue growth (CAGR)
21.55%
3-year earnings per share growth (CAGR)
-4.64%
What the Analysts think about BridgeBio Pharma
Analyst ratings (Buy, Hold, Sell) for BridgeBio Pharma stock.
BridgeBio Pharma Financial Performance
Revenues and expenses
BridgeBio Pharma Earnings Performance
Company profitability
BridgeBio Pharma News
AllArticlesVideos
BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
GlobeNewsWire·5 days ago
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM
GlobeNewsWire·3 weeks ago
Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BridgeBio Pharma stock?
BridgeBio Pharma (BBIO) has a market cap of $7.3B as of June 07, 2025.
What is the P/E ratio for BridgeBio Pharma stock?
The price to earnings (P/E) ratio for BridgeBio Pharma (BBIO) stock is 0 as of June 07, 2025.
Does BridgeBio Pharma stock pay dividends?
No, BridgeBio Pharma (BBIO) stock does not pay dividends to its shareholders as of June 07, 2025.
When is the next BridgeBio Pharma dividend payment date?
BridgeBio Pharma (BBIO) stock does not pay dividends to its shareholders.
What is the beta indicator for BridgeBio Pharma?
BridgeBio Pharma (BBIO) has a beta rating of 1.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.